Pfizer 20-valent Pneumococcal Conjugate Vaccine Phase 3 Clinical Results Positive

On September 29, 2021, Pfizer announced that a phase 3 clinical trial of the 20-valent pneumococcal conjugate vaccine Prevnar 20 has achieved positive top-line results

A total of 1796 subjects were enrolled in this trial, and 1727 subjects completed the trial

Prevnar 20 is Pfizer's next-generation pneumococcal conjugate vaccine, containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14) included in Prevnar 13 (13-valent pneumococcal conjugate vaccine) , 18C, 19A, 19F, and 23F) capsular polysaccharide conjugates, and also contain the capsular polysaccharide conjugates of the other 7 serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that cause invasive pneumococcal disease They are associated with high mortality, antibiotic resistance, and/or meningitis

Reference materials:

[1] Positive Top-Line Results Of Pfizer'S Phase 3 Study Exploring Coadministration Of Prevnar 20™ With Seasonal Flu Vaccine In Older Adults Released.

(The original text has been deleted)